KLP Kapitalforvaltning AS Acquires Shares of 6,600 Capricor Therapeutics Inc (NASDAQ:CAPR)

KLP Kapitalforvaltning AS bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, Holdings Channel reports. The fund bought 6,600 shares of the biotechnology company’s stock, valued at approximately $91,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its position in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after acquiring an additional 111,291 shares during the period. Black Diamond Financial LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $3,833,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Capricor Therapeutics by 51.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after purchasing an additional 37,868 shares during the period. Oppenheimer & Co. Inc. grew its position in Capricor Therapeutics by 52.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock valued at $1,438,000 after buying an additional 35,823 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Capricor Therapeutics by 32.6% during the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock worth $1,160,000 after buying an additional 20,638 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 5.5 %

Shares of CAPR stock opened at $8.88 on Friday. The stock has a market cap of $405.60 million, a P/E ratio of -8.38 and a beta of 4.65. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a fifty day simple moving average of $12.83 and a 200-day simple moving average of $15.15.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. On average, sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.